The Immunome Investment Opportunity: A New Frontier in Biotech? Immunome, Inc.
, a biotech firm focused on developing antibody drug conjugates and other oncology therapeutics, has caught the attention of Aristotle Capital Management's Core Equity Fund.
In its first quarter 2026 investor letter, the fund highlighted Immunome as a "compelling investment opportunity. " The company's market capitalization is $2.